Gilenya was first approved in 2010 and has been a big brand for Novartis, although it is facing strong competition from newer drugs such as Roche's Ocrevus (ocrelizumab), Merck KGaA's Mavenclad ...

Gilenya is Novartis' third-biggest product and the top seller in its neuroscience franchise, bringing in revenues of almost $2.8 billion in 2021, although sales have started to decline due to ...

The risk of disease activity in going to a less effective DMT was higher in younger adults and those having prior ...

You disconnect your cell phone from its charger as you get ready for a busy day. But even though it has been connected all night, the battery is only partially charged. You look at ...

In 2010, multiple sclerosis [MS] had its first oral drug, fingolimod [Gilenya], [approved]. I happened to meet with one of my mentors, Timothy Vollmer, MD, who’s now retired, and we started ...